Skip to content
Business

Viking Therapeutics Raises $575m After Its Obesity Drug Holds Weight Off on Monthly Doses

Viking Therapeutics sold $316m of shares at $35 and $259m of 2% convertible notes, priced a day after data showing patients kept most of their weight loss on monthly or every-other-week VK2735 doses.

Line chart of Viking Therapeutics daily closing prices in the three months to 29 September 2026
Chart: BMK News, exchange data

Viking Therapeutics has raised about $575m before costs by selling shares and convertible notes, priced the day after it reported that patients on its experimental obesity drug VK2735 kept most of their weight loss on less frequent doses. A filing on 28 September confirmed that both offerings, enlarged by the underwriters' options, closed on 25 September.

The maintenance data

On 22 September Viking reported topline results from the first part of its VK2735 maintenance study, a placebo-controlled trial in about 180 adults with obesity. VK2735 is an injected drug that acts on two gut hormone receptors, GLP-1 and GIP, and is already in Phase 3 trials for obesity.

For the first 21 weeks, participants received weekly injections. People on VK2735 lost about 16% to 19% of their body weight on average depending on dose, against roughly no change on placebo. Across the treated groups, 90% lost at least 10% of their weight and 32% lost at least 20%.

They were then switched for 12 weeks to monthly or every-other-week doses, kept on weekly doses, or moved to placebo. The study measured how much of the week-21 weight loss people still had at week 33.

Maintenance armShare of weight loss kept at week 33
Placebo61%
Every other week, all doses90%
Every other week, by dose83% to 97%
Monthly, all doses85%
Monthly, by dose82% to 90%

A small group kept on weekly 17.5 mg doses had lost 21.7% of their starting weight by week 33, with no plateau yet. Viking said gastrointestinal side effects during maintenance were not meaningfully different from placebo. One participant in the every-other-week groups and one in the monthly groups stopped treatment because of a side effect.

Louis Aronne, an obesity specialist who is a paid consultant to Viking, said: "Flexibility for patients and providers is paramount for achieving treatment persistence."

The results have limits. They are company-reported topline numbers, the maintenance arms had only about 10 to 16 people each, and the maintenance period lasted 12 weeks. Viking plans a second part of the study to test oral maintenance doses.

Viking Therapeutics: share price, chart and news

The share sale and the convertible notes

September financing

  • $316.2m from 9.04m new shares sold at $35.00
  • $258.75m of 2.00% convertible notes due 2032
  • About $548m combined net proceeds

Morgan Stanley and J.P. Morgan led both deals. The deals were priced on 23 September. Viking sold 7,857,143 shares at $35.00 each, and the underwriters took up their full option on 1,178,571 more on 24 September, for 9,035,714 shares in total and about $297.0m of net proceeds.

The notes started at $225m, and the underwriters also exercised their full $33.75m option. They pay 2.00% a year, every April and October from April 2027, and mature on 15 October 2032. Each $1,000 note converts into 19.7044 shares, a conversion price of about $50.75, roughly 45% above the price of the share sale. Viking can settle conversions in cash, shares or both, and it can redeem the notes from 22 October 2029 if its shares trade above 130% of the conversion price under set conditions. Net proceeds from the notes were about $250.8m.

Viking plans to spend the money on developing and preparing VK2735 for sale, on its amylin-based programme VK3019, and on general research, working capital and corporate costs.

What it means for shareholders

The share sale added about 9.04m shares, and if every note were converted into stock, it would create about 5.1m more. In return, Viking has a much larger cash buffer to fund two late-stage obesity trials, VANQUISH-1 and VANQUISH-2, which test weekly VK2735 injections over 78 weeks.

Viking has no approved product and no sales, and its spending on Phase 3 trials is large. Its drug would also have to compete with weight-loss treatments that are already on the market from much larger companies. The notes add a fixed interest cost and a repayment due in 2032 if they are not converted.

What to watch

  • Results from the larger VANQUISH Phase 3 trials
  • The second part of the maintenance study, which tests oral maintenance doses
  • Progress on oral VK2735 and on VK3019
  • How much of the new cash Viking spends each quarter

Sources

Related stories

Investing

Viking Therapeutics Investor Profile: VK2735, Two Phase 3 Programmes and $960m of Cash

Viking Therapeutics is testing obesity drug VK2735 in Phase 3 as a weekly injection and a daily pill. It had $960m of cash at the end of September but lost $183.2m in the third…

Business

Kraig Biocraft Laboratories Ships Its First Commercial Spider Silk Yarn Order

Kraig Biocraft Laboratories has shipped its first commercial order of spider silk yarn to an unnamed sports brand, but gave no volume or price and reported no revenue in the first…

Business

Novo Nordisk Shares Slump as Investors Shrug Off 2030 Blockbuster Targets

Novo Nordisk targeted more than five blockbusters by 2030 and over DKK 150 billion of pipeline sales in 2035, but its shares fell as much as 9 percent as investors questioned the…

Business

Telix Agrees to Buy Munich Isotope Maker ITM for Up to $2.35bn

Australia's Telix Pharmaceuticals agreed to buy ITM Isotope Technologies Munich for $1.65 billion upfront, mostly in shares, plus up to $700 million tied to its lead cancer drug.

Business

Québecor Makes a C$31bn Cash-and-Share Bid for Telus, Which Warns of Regulatory Risk

Québecor has offered C$6.35 in cash plus 0.17 of its own shares for each Telus share, a bid worth about C$31bn. The Telus board says the price falls short and the regulatory risk…

Business

Tyson Foods Shares Jump 8.7% as Beef Outlook Outweighs a $74m Quarterly Loss

Tyson Foods posted a $74m fourth-quarter net loss and adjusted EPS of $0.61, down 47%, yet its shares closed 8.7% higher on Monday as its 2027 beef outlook pointed to far smaller…

Business

Roche Wins FDA Approval for Breast Cancer Pill Wilserdly After 62% Cut in Progression Risk

The FDA approved Roche's all-pill Wilserdly combination for ESR1-mutated advanced breast cancer after it cut the risk of progression or death by 62%. A ruling on early-stage use is…

Business

ULA Loses Its First Mission as Vulcan Rocket Fails With 40 Amazon Leo Satellites on Board

United Launch Alliance's Vulcan rocket failed about 10 minutes after lift-off on Sunday, and all 40 Amazon Leo satellites were lost. Amazon fell 3.3% on Monday as space stocks…